TY  - JOUR
AU  - Roberto, Attanasio
AU  - Miloš, Žarković
AU  - Enrico, Papini
AU  - Nagy, Endre
AU  - Roberto, Negro
AU  - Petros, Perros
AU  - Ersin, Akarsu
AU  - Maria, Alevizaki
AU  - Göksun, Ayvaz
AU  - Tomasz, Bednarczuk
AU  - Biljana, Beleslin
AU  - Berta, Eszter
AU  - Bodor, Miklós
AU  - Anna, Maria Borissova
AU  - Mihail, Boyanov
AU  - Camille, Buffet
AU  - Maria-Cristina, Burlacu
AU  - Jasmina, Ciric
AU  - Juan, J. Díez
AU  - Harald, Dobnig
AU  - Valentin, V. Fadeyev
AU  - Benjamin, C. T. Field
AU  - Eric, Fliers
AU  - Dagmar, Führer
AU  - Juan, Carlos Galofré
AU  - Tommi, Hakala
AU  - Jan, Jiskra
AU  - Peter, A. Kopp
AU  - Michael, Krebs
AU  - Michal, Kršek
AU  - Martin, Kuzma
AU  - Mikael, Lantz
AU  - Ivica, Lazúrová
AU  - Laurence, Leenhardt
AU  - Vitaliy, Luchytskiy
AU  - Francisca, Marques Puga
AU  - Anne, McGowan
AU  - Saara, Metso
AU  - Carla, Moran
AU  - Tatyana, Morgunova
AU  - Dan, Alexandru Niculescu
AU  - Božidar, Perić
AU  - Tereza, Planck
AU  - Catalina, Poiana
AU  - Eyal, Robenshtok
AU  - Patrick, Olivier Rosselet
AU  - Marek, Ruchala
AU  - Kamilla, Ryom Riis
AU  - Alla, Shepelkevich
AU  - Mykola, D. Tronko
AU  - David, Unuane
AU  - Irfan, Vardarli
AU  - W., Edward Visser
AU  - Andromachi, Vryonidou
AU  - Younes, Ramazan Younes
AU  - Laszlo, Hegedus
TI  - Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists :$bThe "THESIS"* collaboration (*Treatment of Hypothyroidism in Europe by Specialists, an International Survey)
JF  - THYROID
J2  - THYROID
PY  - 2024
SN  - 1050-7256
UR  - https://m2.mtmt.hu/api/publication/34747533
ID  - 34747533
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Ratku, Balázs
AU  - Lőrincz, Hajnalka
AU  - Bak-Csiha, Sára
AU  - Sebestyén, Veronika
AU  - Berta, Eszter
AU  - Bodor, Miklós
AU  - Nagy, Endre
AU  - Szabó, Zoltán
AU  - Harangi, Mariann
AU  - Somodi, Sándor
TI  - Serum afamin and its implications in adult growth hormone deficiency: a prospective GH-withdrawal study
JF  - FRONTIERS IN ENDOCRINOLOGY
J2  - FRONT ENDOCRINOL
VL  - 15
PY  - 2024
SN  - 1664-2392
DO  - 10.3389/fendo.2024.1348046
UR  - https://m2.mtmt.hu/api/publication/34564621
ID  - 34564621
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Žarković, Miloš
AU  - Attanasio, Roberto
AU  - Nagy, Endre
AU  - Negro, Roberto
AU  - Papini, Enrico
AU  - Perros, Petros
AU  - Cohen, Chagit Adler
AU  - Akarsu, Ersin
AU  - Alevizaki, Maria
AU  - Ayvaz, Göksun
AU  - Bednarczuk, Tomasz
AU  - Berta, Eszter
AU  - Bodor, Miklós
AU  - Borissova, Anna Maria
AU  - Boyanov, Mihail
AU  - Buffet, Camille
AU  - Burlacu, Maria-Cristina
AU  - Ćirić, Jasmina
AU  - Díez, Juan J.
AU  - Dobnig, Harald
AU  - Fadeyev, Valentin
AU  - Field, Benjamin C. T.
AU  - Fliers, Eric
AU  - Frølich, Jacob Stampe
AU  - Führer, Dagmar
AU  - Galofré, Juan Carlos
AU  - Hakala, Tommi
AU  - Jiskra, Jan
AU  - Kopp, Peter
AU  - Krebs, Michael
AU  - Kršek, Michal
AU  - Kužma, Martin
AU  - Lantz, Mikael
AU  - Lazúrová, Ivica
AU  - Leenhardt, Laurence
AU  - Luchytskiy, Vitaliy
AU  - McGowan, Anne
AU  - Melo, Miguel
AU  - Metso, Saara
AU  - Moran, Carla
AU  - Morgunova, Tatyana
AU  - Mykola, Tronko
AU  - Beleslin, Biljana Nedeljković
AU  - Niculescu, Dan Alexandru
AU  - Perić, Božidar
AU  - Planck, Tereza
AU  - Poiana, Catalina
AU  - Puga, Francisca Marques
AU  - Robenshtok, Eyal
AU  - Rosselet, Patrick
AU  - Ruchala, Marek
AU  - Riis, Kamilla Ryom
AU  - Shepelkevich, Alla
AU  - Unuane, David
AU  - Vardarli, Irfan
AU  - Visser, W. Edward
AU  - Vrionidou, Andromachi
AU  - Younes, Younes R.
AU  - Yurenya, Elena
AU  - Hegedüs, Laszlo
TI  - Characteristics of specialists treating hypothyroid patients: the “THESIS” collaborative
JF  - FRONTIERS IN ENDOCRINOLOGY
J2  - FRONT ENDOCRINOL
VL  - 14
PY  - 2023
SP  - 1
EP  - 11
PG  - 11
SN  - 1664-2392
DO  - 10.3389/fendo.2023.1225202
UR  - https://m2.mtmt.hu/api/publication/34484390
ID  - 34484390
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Dániel, Eszter
AU  - Nagy, B. Edit
AU  - Nagy, Endre
AU  - Erdei, Annamária
TI  - Kezelés nélkül javuló acromegalia a pandémia alatt
JF  - METABOLIZMUS
J2  - METABOLIZMUS
VL  - 21
PY  - 2023
IS  - 2
SP  - 86
EP  - 89
PG  - 4
SN  - 1589-7311
UR  - https://m2.mtmt.hu/api/publication/34391921
ID  - 34391921
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Cassemiro, Jessica F.
AU  - Ilera, Veronica
AU  - Batalles, Stella
AU  - Reyes, Adriana
AU  - Nagy, Endre
AU  - Papini, Enrico
AU  - Perros, Petros
AU  - Hegedus, Laszlo
AU  - Ramos, Helton Estrela
TI  - Use of thyroid hormones in hypothyroid and euthyroid patients: a 2022 THESIS questionnaire survey of members of the Latin American Thyroid Society (LATS)
JF  - THYROID RESEARCH
J2  - THYROID RES
VL  - 16
PY  - 2023
IS  - 1
PG  - 9
SN  - 1756-6614
DO  - 10.1186/s13044-023-00182-4
UR  - https://m2.mtmt.hu/api/publication/34347406
ID  - 34347406
AB  - PurposeInconsistencies in the medical management of hypothyroidism have been reported between endocrinologists in different countries. This study aimed to identify the attitudes of Latin America thyroid specialists towards the use of thyroid hormones.MethodsOnline survey of members of the Latin America Thyroid Society.Results81/446 (18.2%) completed the questionnaire. Levothyroxine (LT4) was the initial treatment of choice for all respondents. 56.8% would consider LT4 use in biochemically euthyroid patients: infertile women with elevated anti-thyroid antibodies (46.9%), resistant depression (17.3%) and growing goiter (12%). Most respondents preferred tablets (39.5%) over liquid formulations (21.0%) or soft gel capsules (22.2%) and would not consider switching formulations in patients with persistent symptoms. 39.5% would never use LT4 + liothyronine (LT3) combination therapy in symptomatic euthyroid patients, due to low quality evidence for benefit. 60.5% reported that persistence of symptoms despite normal TSH is rare (below 5% of patients) and its prevalence has been stable over the last five years. Psychosocial factors (84.0%), comorbidities (86.4%) and the patient unrealistic expectation (72.8%) were considered the top three explanations for this phenomenon.ConclusionLT4 tablets is the treatment of choice for hypothyroidism. A significant proportion of respondents would use LT4 in some groups of euthyroid individuals, contrasting the recommendations of the major clinical practice guideline indications. LT4 + LT3 combination treatment in euthyroid symptomatic patients was considered by nearly 50%. Practices based on weak or absent evidence included use of thyroid hormones for euthyroid subjects by 56.8% of respondents and use of LT4 + LT3 treatment by 60.5% of respondents for patients with persistent symptoms. In contrast to many European countries, LATS respondents report a low and unchanged proportion of dissatisfied patients over the last five years.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Ratku, Balázs
AU  - Sebestyén, Veronika
AU  - Szelesné Árokszállási, Andrea
AU  - Erdei, Annamária
AU  - Berta, Eszter
AU  - Szabó, Zoltán
AU  - Bodor, Miklós
AU  - Nagy, Endre
AU  - Somodi, Sándor
TI  - A felnőttkori növekedésihormon-hiány szív- és érrendszeri szövődményei
JF  - ORVOSI HETILAP
J2  - ORV HETIL
VL  - 164
PY  - 2023
IS  - 41
SP  - 1616
EP  - 1627
PG  - 12
SN  - 0030-6002
DO  - 10.1556/650.2023.32890
UR  - https://m2.mtmt.hu/api/publication/34280731
ID  - 34280731
AB  - A növekedési hormon–inzulinszerű növekedési faktor-1 (GH–IGF-1-) tengely jelentős szerepet tölt be a cardiovascularis rendszer fiziológiás működésének fenntartásában. Az elmúlt évtizedek kutatási eredményei alapján a GH–IGF-1-tengely részt vesz a perifériás ellenállás szabályozásában, és hozzájárul a normális szívizomtömeg és balkamra-funkció megtartásához. A GH–IGF-1-tengely érfalprotektív funkciói az atherosclerosis ellenében hatnak. Ellentétben a gyermekkori GH-hiánnyal, amelynél a betegség egyértelmű biológiai következménye a gyermek növekedésbeli visszamaradása, a felnőttkori növekedésihormon-hiánynak (adult growth hormone deficiency – AGHD) nincsenek specifikus tünetei. Az AGHD klinikai megjelenését a cardiovascularis rizikótényezők halmozódása jellemzi, amely miatt a klinikai kép leginkább a metabolicus szindrómához hasonlítható. Újabb kutatások AGHD esetében a tradicionális rizikótényezők mellett krónikus kisfokú gyulladás, prothromboticus állapot és oxidatív stressz jelenlétére is rámutattak, amelyek szintén közrejátszhatnak a fokozott kardiometabolikus rizikó kialakulásában. A tartós GH-szubsztitúció AGHD-betegek esetében a lipidprofil jelentős javulását eredményezi, és kedvező hatással van a testösszetételre, a szívizomtömegre, az endothelfunkcióra, valamint az újonnan felismert, nem tradicionális rizikótényezőkre is. A betegséggel összefüggő fokozott mortalitás a mai felfogás szerint multikauzális, és nem vezethető vissza csupán a GH hiányára. A kedvezőtlen mortalitásért az etiológia, az alkalmazott kezelés és az egyéb hypophysishormon-hiányok kezelésének nehézsége is felelős lehet. Mindazonáltal hypopituitarismus esetében optimális, a GH-pótlást is magában foglaló hormonszubsztitúcióval az átlagpopulációéhoz közelítő mortalitás érhető el. Orv Hetil. 2023; 164(41): 1616–1627.
LA  - Hungarian
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Szántó, Dorottya
AU  - Luterán, Péter
AU  - Gál, Judit
AU  - Nagy, Endre
AU  - Fülesdi, Béla
AU  - Molnár, Csilla
TI  - Diagnosis and Management of Takotsubo Syndrome in Acute Aneurysmal Subarachnoid Hemorrhage: A Comprehensive Review
JF  - REVIEWS IN CARDIOVASCULAR MEDICINE
J2  - REV CARDIOVASC MED
VL  - 24
PY  - 2023
IS  - 6
PG  - 12
SN  - 1530-6550
DO  - 10.31083/j.rcm2406177
UR  - https://m2.mtmt.hu/api/publication/34039103
ID  - 34039103
AB  - Takotsubo syndrome (TS) is a frequent complication of subarachnoid hemorrhage (SAH), especially in massive SAH with severe neuro-logical damage. The initial presentation of TS is similar to acute coronary syndrome, causing differential diagnostic issues. Unnecessary diagnostic steps and uncertainty in therapy may delay the definitive treatment of the aneurysm, therefore increasing the risk of rebleeding. The purpose of this review is to summarize the latest knowledge on the diagnosis and therapy of TS in SAH and to provide a diagnostic and therapeutic algorithm for the acute phase, promoting the early definitive treatment of the aneurysm. Rapid hemodynamic stabilization and early aneurysm securing are key points in reducing the risk of delayed cerebral ischemia and improving outcomes. In acute SAH noninvasive bedside diagnostic methods are preferred and securing the aneurysm is the priority. The combination of electrocardiography, cardiac biomarkers, and echocardiography is of great importance in differentiating TS from acute myocardial infarction. The risk-benefit ratio of coronary angiography should be carefully and individually considered and its use should be limited to patients with strong evi-dence of myocardial ischemia, after the successful endovascular treatment of the aneurysm. Invasive hemodynamic monitoring may be beneficial in cases of cardiogenic shock or pulmonary edema. In patients with hemodynamical instability secondary to TS, the use of non-catecholamine inotropes, especially levosimendan is recommended. In refractory hypotension, mechanical support should be con-sidered. The left ventricular function improves within days to months after the acute event, low initial ejection fraction may predispose to delayed recovery.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Perros, Petros
AU  - Nagy, Endre
AU  - Papini, Enrico
AU  - van der Feltz-Cornelis, Christina Maria
AU  - Weetman, Anthony Peter
AU  - Hay, Harriet Alexandra
AU  - Abad-Madronero, Juan
AU  - Tallett, Amy Johanna
AU  - Bilas, Megan
AU  - Lakwijk, Peter
AU  - Poots, Alan J.
AU  - Hegedus, Laszlo
TI  - Hypothyroidism and Somatization: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey
JF  - THYROID
J2  - THYROID
VL  - 33
PY  - 2023
IS  - 8
SP  - 927
EP  - 939
PG  - 13
SN  - 1050-7256
DO  - 10.1089/thy.2022.0641
UR  - https://m2.mtmt.hu/api/publication/33870288
ID  - 33870288
AB  - Background: Between 10% and 15% of hypothyroid patients experience persistent symptoms despite achieving biochemical euthyroidism. Unexplained persistent symptoms can be a sign of somatization. This is associated with distress and high health care resource use and can be classified as somatic symptom disorder (SSD). Prevalence rates for SSD differ depending on classification criteria and how they are ascertained, varying between 4% and 25%. As this has not been studied in hypothyroid patients before, the aim of this study was to document somatization in people with hypothyroidism and to explore associations with other patient characteristics and outcomes.Methods: Online, multinational cross-sectional survey of individuals with self-reported, treated hypothyroidism, which included the validated Patient Health Questionnaire-15 (PHQ-15) for assessment of somatization. Chi-squared tests with the Bonferroni correction were used to explore outcomes for respondents with a PHQ-15 score >= 10 (probable somatic symptom disorder [pSSD]) versus a PHQ-15 score <10 (absence of SSD).Results: A total of 3915 responses were received, 3516 of which contained the valid PHQ-15 data (89.8%). The median score was 11.3 (range 0-30 [confidence interval 10.9-11.3]). The prevalence of pSSD was 58.6%. Associations were found between pSSD and young age (p < 0.001), women (p < 0.001), not working (p < 0.001), having below average household income (p < 0.001), being treated with levothyroxine (LT4) (rather than combination of LT4 and L-triiodothyronine [LT3], LT3 alone, or desiccated thyroid extract) (p < 0.001), expression of the view that the thyroid medication taken did not control the symptoms of hypothyroidism well (p < 0.001), and with number of comorbidities (p < 0.001). pSSD was associated with respondent attribution of most PHQ-15 symptoms to the hypothyroidism or its treatment (p < 0.001), dissatisfaction with care and treatment of hypothyroidism (p < 0.001), a negative impact of hypothyroidism on daily living (p < 0.001), and with anxiety and low mood/depression (p < 0.001).Conclusions: This study demonstrates a high prevalence of pSSD among people with hypothyroidism and associations between pSSD and negative patient outcomes, including a tendency to attribute persistent symptoms to hypothyroidism or its treatment. SSD may be an important determinant of dissatisfaction with treatment and care among some hypothyroid patients.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Sira, Lívia
AU  - Zsíros, Noémi
AU  - Bidiga, László
AU  - Barna, Sándor Kristóf
AU  - Kanyári, Zsolt
AU  - Nagy, Edit B.
AU  - Guillaume, Nicolas
AU  - Wild, Damian
AU  - Rázsó, Katalin
AU  - Andó, Szilvia
AU  - Balogh, István
AU  - Nagy, Endre
AU  - Balogh, Zoltán
TI  - Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies
JF  - FRONTIERS IN ENDOCRINOLOGY
J2  - FRONT ENDOCRINOL
VL  - 14
PY  - 2023
PG  - 7
SN  - 1664-2392
DO  - 10.3389/fendo.2023.1095815
UR  - https://m2.mtmt.hu/api/publication/33699902
ID  - 33699902
AB  - Background: Splanchnic vein thrombosis due to co-existing metastatic pancreatic neuroendocrine tumour (pNET) and JAK2V617F mutation is a rare condition. Case report: Here we present a case of a young woman with complete remission of a non-functioning grade 2 pNET with unresectable liver metastases, coexisting with JAK2V617F mutation. Splenectomy and distal pancreatectomy were performed. Neither surgical removal, nor radiofrequency ablation of the liver metastases was possible. Therefore, somatostatin analogue (SSA) and enoxaparine were started. Peptide receptor radionuclide therapy (PRRT) was given in 3 cycles 6-8 weeks apart. Genetic testing revealed no multiple endocrine neoplasia type 1 (MEN-1) gene mutations. After shared decision making with the patient, she gave birth to two healthy children, currently 2 and 4 years old. On pregnancy confirmation, SSA treatment was interrupted and resumed after each delivery. Ten years after the diagnosis of pNET, no tumour is detectable by MRI or somatostatin receptor scintigraphy. PRRT followed by continuous SSA therapy, interrupted only during pregnancies, resulted in complete remission and enabled the patient to complete two successful pregnancies.
LA  - English
DB  - MTMT
ER  - 

TY  - JOUR
AU  - Solymosi, Tamás
AU  - Hegedűs, Laszlo
AU  - Bonnema, Steen J
AU  - Frasoldati, Andrea
AU  - Jambor, Laszlo
AU  - Karányi, Zsolt
AU  - Kovacs, Gabor L
AU  - Papini, Enrico
AU  - Rucz, Károly
AU  - Russ, Gilles
AU  - Nagy, Endre
TI  - Considerable interobserver variation calls for unambiguous definitions of thyroid nodule ultrasound characteristics.
JF  - EUROPEAN THYROID JOURNAL
J2  - EUR THYROID J
VL  - 12
PY  - 2023
IS  - 2
PG  - 11
SN  - 2235-0640
DO  - 10.1530/ETJ-22-0134
UR  - https://m2.mtmt.hu/api/publication/33602815
ID  - 33602815
AB  - Thyroid nodule ultrasound characteristics are used as indication for FNA, usually as the basis for Thyroid Imaging Reporting and Data System (TIRADS) score calculation. Few studies on inter-observer variation are available, all of which are based on analysis of preselected still ultrasound images and often lack surgical confirmation.After the blinded online evaluation of video-recordings of the ultrasound examinations of 47 consecutive malignant and 76 consecutive benign thyroid lesions, 7 experts from 7 thyroid centers answered 17 TIRADS-related questions. Surgical histology was the reference standard. Inter-observer variations of each ultrasound characteristic were compared using Gwet's AC1 inter-rater coefficients; higher values mean better concordance, the maximum being 1.0.On a scale from 0.0 to 1.0, the Gwet's AC1 values were 0.34, 0.53, 0.72, 0.79 for the four most important features in decision making, i.e. irregular margins, microcalcifications, echogenicity and extrathyroidal extension, respectively. The concordance in the discrimination between mildly/moderately and very hypoechogenic nodules was 0.17. The smaller the nodule size the better the agreement in echogenicity, and the larger the nodule size the better the agreement on the presence of microcalcifications. Extrathyroidal extension, was correctly identified in just 45.8% of the cases.Examination of video recordings, closely simulating the real-world situation, revealed substantial inter-observer variation in the interpretation of each of the four most important ultrasound characteristics. In view of the importance for management of thyroid nodules, unambiguous and widely accepted definitions of each nodule characteristic are warranted, although it remains to be investigated whether this diminishes observer-variation.
LA  - English
DB  - MTMT
ER  -